BTCY:NSD-Biotricity Inc. Common Stock (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 1.23

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

0.06M

Avg Analyst Target

USD 5.50 (+347.15%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Biotricity Inc. Common Stock (BTCY) Stock Analysis:
Based on the Biotricity Inc. Common Stock stock forecasts from 2 analysts, the average analyst target price for Biotricity Inc. Common Stock is USD 5.50 over the next 12 months. Biotricity Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biotricity Inc. Common Stock is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Biotricity Inc. Common Stock’s stock price was USD 1.23. Biotricity Inc. Common Stock’s stock price has changed by +8.85% over the past week, -32.04% over the past month and -52.33% over the last year.

About

Biotricity, Inc., medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutio ...Read More

Company Website : https://www.biotricity.com

Address : 275 Shoreline Drive, Redwood City, CA, United States, 94065

Employees : 44

Fiscal Year End : March

Currency: USD

Country : USA

Technical Indicators

Beta : 2.41

52 Week High : 5.30

Short Ratio : 9.40

52 Week Low : 0.98

Shorted Shares : 950,455

200 Day Moving Average : 3.08

Shorted Shares Previous Month : 1,004,721

50 Day Moving Average : 1.88

Shares Held By Insiders : 15.08%

Short Percentage : 2.10%

Shares Held by Institutions : 5.71%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

N/A

 USD31.52B 164.23 78.28
ALGN Align Technology Inc

N/A

 USD21.67B 30.96 19.14
LVGO Livongo Health, Inc

N/A

 USD14.20B N/A N/A
PODD Insulet Corporation

N/A

 USD13.78B 310.99 85.34
ABMD Abiomed Inc

N/A

 USD10.74B 79.11 39.39
BRKR Bruker Corporation

N/A

 USD9.05B 32.74 18.24
SWAV ShockWave Medical Inc

N/A

 USD5.73B 196.35 154.44
IART Integra LifeSciences Holdings ..

N/A

 USD4.96B 32.41 17.44
TNDM Tandem Diabetes Care Inc

N/A

 USD4.67B 820.11 190.18
IRTC iRhythm Technologies Inc

N/A

 USD4.07B N/A N/A

ETFs Containing BTCY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -69.10% 9% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.10% 9% F 9% F
Trailing 12 Months  
Capital Gain -52.33% 49% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.33% 49% F 30% F
Trailing 5 Years  
Capital Gain -56.99% 33% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.99% 33% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain 45.94% 75% C 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.94% 75% C 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 121.10% 22% F 11% F
Risk Adjusted Return 37.93% 60% D- 66% D
Market Capitalization 0.06B 35% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 24.82 6% F 3% F
Price / Cash Flow Ratio -5.70 65% D 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -4,100.79% 1% F 0% N/A
Return on Invested Capital 856.89% 100% A+ 99% A+
Return on Assets -76.38% 4% F 2% F
Debt to Equity Ratio -5.43% 93% A 92% A-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 9.40 17% F 11% F
Short Percent 2.10% 72% C- 58% F
Beta 2.41 9% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector